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Abstract: The current pilot study investigates whether oral supplementation of specific collagen
peptides improves symptoms and tendon vascularisation in patients with chronic mid-portion
Achilles tendinopathy in combination with structured exercise. Participants were given a placebo
or specific collagen peptides (TENDOFORTE®) in combination with a bi-daily calf-strengthening
program for 6 months. Group AB received specific collagen peptides for the first 3 months before
crossing over to placebo. Group BA received placebo first before crossing over to specific collagen
peptides. At baseline (T1), 3 (T2) and 6 (T3) months, Victorian Institute of Sports Assessment–Achilles
(VISA-A) questionnaires and microvascularity measurements through contrast-enhanced ultrasound
were obtained in 20 patients. Linear mixed modeling statistics showed that after 3 months, VISA-A
increased significantly for group AB with 12.6 (9.7; 15.5), while in group BA VISA-A increased only by
5.3 (2.3; 8.3) points. After crossing over group AB and BA showed subsequently a significant increase
in VISA-A of, respectively, 5.9 (2.8; 9.0) and 17.7 (14.6; 20.7). No adverse advents were reported.
Microvascularity decreased in both groups to a similar extent and was moderately associated with
VISA-A (Rc2:0.68). We conclude that oral supplementation of specific collagen peptides may accelerate
the clinical benefits of a well-structured calf-strengthening and return-to-running program in Achilles
tendinopathy patients.
Keywords: achilles tendon; microvessels; contrast-enhanced ultrasound; hydrolysed collagen
supplementation
1. Introduction
The treatment of chronic Achilles tendinopathy remains challenging with a relatively high
percentage of non-responders. There are many proposed treatment options, of which an eccentric
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exercise program is currently the first treatment of choice. Despite the good results on pain scores after
eccentric exercises, a 5-year follow-up study showed that only ~40% of the patients were completely
pain free and 48% had received one or more alternative treatments [1]. In accordance with this,
there is still a need for treatments that would improve the benefits of a structured eccentric exercise
program. Recent studies indicate that both cardiometabolic [2,3], as well as nutritional factors [4,5]
can modulate local tendon healing. Although clinical studies are still scarce, a recent International
Olympic Committee (IOC) consensus statement on dietary supplements in high-performance
athletes [6] proposes that dietary supplementation containing gelatin or hydrolysed collagen could
potentially be useful for athletic populations as increased intake of collagen-derived peptides has
been shown to modulate collagen synthesis [7] and reduce tendon- [8] and joint-related pain [9,10].
Others have shown that glycine, as the most abundant component of collagen hydrolysates [11],
has disease-modifying properties in both animal [12,13] and in vitro [14] models of tendinopathy.
There is also first evidence, that collagen peptides might improve functional ankle properties in
chronic ankle instability [15]. Therefore, we aimed to study the potential clinical benefits of a specific
porcine-derived hydrolysed collagen supplement as add-on therapy to 6 months of an eccentric
calf-strengthening and well-structured return-to-running program.
It has been well established that increased (micro) vascularity is associated with chronic
(painful) tendon lesions [16]. As a change in (micro)vascularity might be a hinge for improved
tendon architecture, our aim was to check whether the oral intake of collagen peptides influence
microvascular changes in tendinopathic areas of the Achilles tendon using real-time contrast-enhanced
ultrasonography (CEUS) [17]. In a recently published study [18], it was shown that CEUS provides a
more objective and reproducible assessment of tendon microvascularity in comparison with power
Doppler ultrasound. Furthermore, CEUS was also shown to be moderately associated with increased
Achilles tendon symptoms. We hypothesized that improvements in tendon pain and function
throughout the course of the intervention would be reflected by a reduction in CEUS-based tendon
microvascularity. A previous ultrasonographic tissue characterisation study has shown that structural
integrity is decreased in both Achilles tendons in people with unilateral Achilles tendinopathy [19].
As dietary supplementation of hydrolysed collagen appears to have systemic effects on collagen-dense
tissue [20–22], we aimed to study both tendons of each individual patient, independent of whether
participants had uni- or bilateral symptoms.
2. Methods
The current study is a prospective double-blinded placebo-controlled clinical trial with a
cross-over design. Through balanced within block-randomization (computer-based, 5 individuals per
block), eligible participants were allocated to each study arm by an independent staff member to either
3 months of bi-daily 2.5 g hydrolysed specific collagen peptides (sCP) (TENDOFORTE®, GELITA
AG) or a placebo product to be dissolved in water, both pre-packed in identical sachets (see also
study flow diagram Figure 1). The bi-daily intake of sCPs was based on the pharmacokinetic profile;
the placebo sachets contained 2.5 g of maltodextrin (CARGILL) obtained by enzymatic conversion
of starch. The sachets containing sCP or placebo were absolutely identical in appearance and the
products were equal in flavor and texture. After 3 months, participants who received the sCPs were
crossed-over to the placebo product (group AB) and vice versa (group BA). Allocation concealment
was further ascertained by allocating an individual to group AB or group BA. No patient, research
nurse, assessor or any other medical or research staff was aware of the treatment assignments for the
duration of the study. All data and statistical analyses were also completed before the randomization
code was broken at the end of the completed trial [23]. Based on lack of previous data sets that allowed
for a power analysis and sample size calculation, we designed a small-scale pilot study with multiple
outcome measures that involved 2 groups of 10 participants. Data collection of this single-center trial
was performed in an outpatient sports medicine clinic of a national high-performance sports institute.
All subjects gave their informed consent for inclusion before they participated in the study. The study
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was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the
local ethics committee of the Australian Institute of Sport (Project ID: 20141201V2) and prospectively
registered (ANZCTR#12615001035516). Patients were not involved in our study design. Participants
were recruited by social media and advertisements. In- and exclusion criteria are summarized in
Appendix A Table A1.
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2.1. Exercise Intervention
In addition to the nutritional intervention, all participants followed a well-structured eccentric
calf-strengthening program and milestone-based return-to-running program for a total duration of
6 months. The eccentric exercise started with a calf raise using the unaffected limb (or both limbs if
the symptoms were bilateral), followed by an eccentric drop using the injured leg. The exercise was
performed with both the knee straight and the knee bent to target the gastrocnemius and soleus muscles
respectively. Over a 6-month period, participants were instructed to perform 2 × 90 repetitions daily,
despite the presence of pain [24]. All participants were instructed to avoid weight-bearing sporting
activities for the first four weeks. When participants reported less than 2 out of 10 pain on single leg
hopping, they were allowed to start with low-intensity running exercises. Details and milestones used
within this program can be found in Appendix A Table A2. Half an hour before the calf-strengthening
exercises, participants were instructed to ingest 2.5 g of sCP or placebo product dissolved in a glass of
cold water. This provides sufficient time for orally ingested sCPs to be absorbed in the gut and appear
in the blood stream [25]. Participants kept a diary of their calf-strengthening exercises and were asked
to return any leftover sachets at both their 3 and 6 months follow-up appointments.
2.2. Outcome Measurements.
All particip nts underwent a series of measurements and evaluations at baseline, 3 and 6 months
to evaluate their response to the combined exercise and nutritional intervention. All measurements
and questionnaires were scheduled within a time frame of 3 days and performed by the same team of
health practitioners and researchers who were blinded for the nutritional intervention and trained in
the standardized operating procedures for the different measurements. Both at 3 and 6 months,
our participants were asked whether they thought they had been taking the sachets with sCPs
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or placebo. At the end of the trial and after deblinding this information was matched with true
allocation order.
2.3. Victorian Institute of Sports Assessment–Achilles (VISA-A) Questionnaire, Patient Satisfaction and
Return-to-Running
One day prior to the ultrasound examinations, all patients were asked to rate their subjective
Achilles tendon pain and functional limitations for both the right and left Achilles tendon separately
using a Victorian Institute of Sports Assessment–Achilles (VISA-A) questionnaire [26]. After 3 and 6
months patients also received a questionnaire to rate their satisfaction and to what level they had been
able to resume their running sports activities (Appendix A Table A3).
2.4. Real-Time Harmonic Contrast Enhanced Ultrasound (CEUS) Measurements
Contrast-enhanced ultrasound (CEUS) measurements scans were performed as described
in previous studies [17,18]. Patients were prone with fully extended knees and both ankles
immobilized with an ankle angle between 5–10 degrees plantar flexion whilst ensuring minimal
tendon tension. Both Achilles tendons were examined in the longitudinal plane with a 58 mm long
high-frequency (5–14 MHz) linear array transducer (model 14L5/PLT-1005BT) on an Aplio™500
(TUS-A500, Toshiba/CANON Medical Systems, Tochigi Otawara, Japan). The transducer was
longitudinally positioned in the Achilles tendon midline using a retort clamp attached to the bed.
A 12G copper wire was placed between transducer, gel and skin to locate and mark tendon insertion in
a reproducible manner. Tendon insertion was defined as the attachment point of most ventral tendon
fibres to the calcaneal bone. A total of seven skin marks at 1-cm intervals were used to position the
ultrasound probe over the tendon mid-portion (2–6 cm). Probe pressure was kept to a minimum to
avoid blood vessel obliteration. Scanning parameters were optimised for 3 cm depth and kept constant
for all participants. Real-time harmonic CEUS of the Achilles tendon mid-portion was performed
through the injection of 10uL.kg-1 body weight bolus of agitated contrast agent (DEFINITY™, Lantheus
Medical Imaging, Billerica North Billerica, MA, USA) in a forearm vein, followed by 10 ml 0.9% saline
solution. CEUS is based on second harmonic imaging of intravascular circulating microbubbles with a
diameter of ~1–3 microns. These microbubbles act as echo-enhancers and are used with the aim to
identify small vessels (down to 40 microns) [18]. Participants were instructed not to talk or change body
position during recordings. Blood pressure and heart rate were measured every 5 min throughout the
procedure with a digital sphygmamometer and automatically inflating arm cuff (OMRON HEM-7130,
Wujia Medical Equipment Co., Ltd., Fengshan District, Kaohsiung City, Taiwan). As peak flow of
CEUS signal was achieved within 2 minutes following the bolus injection, only first 120 s of digital
CEUS data were used for further analysis. To allow for complete washout of perflutren gas through
the lungs, a minimum of 15 min was allowed between consecutive CEUS measurements of right and
left Achilles tendon. Dedicated contrast harmonic image quantification software (2B771-005EN*V,
Toshiba/CANON Medical Systems, Tochigi Otawara, Japan) was used for time-curve analysis (TCA).
In the present study, it involved the examination of a 25 × 13 mm region of interest (ROI) that
included at least 2 mm of the anterior fat pad. Within this ROI, the relative microvascularity (MV)
values were determined as peak log-scaled signal intensity in decibels (dB) of a normalised smoothed
curve during the first 2 min after subtraction of baseline signal intensity 20–25 s after bolus injection.
Inter-observer reliability for CEUS-based MV-values was previously shown to be excellent with an
intraclass correlation (ICC) of 0.97 [17].
2.5. Blood Sampling
At baseline, 3 and 6 months, non-fasting blood samples were obtained from
venipuncture to determine total cholesterol, triglycerides and uric acid and exclude (familial)
hypercholesterolaemia [27] and gout [28] as a contributing factor to tendinopathy. In addition, at each
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time point a 500 µL serum sample was stored at −80 ◦C for further analyses in case of a serious
adverse event related to the intake of the investigational product.
2.6. Product Safety and Monitoring of Adverse Events
Specific collagen peptides are characterized by a considerably high safety profile. So far no clinical
indications of allergies have been observed. No incompatibilities with other diets or medications
have ever been described in the medical literature. Collagen peptides received the GRAS status from
the Food and Drug Administration. “GRAS” is an official abbreviation which stands for “generally
recognized as safe [29]. Nevertheless, participants were instructed to report any gastro-intestinal or
other side effects that they thought were potentially associated with the intake of the investigational
product or placebo.
2.7. Statistical Analyses
All data are presented as means ± standard deviation (SD), unless indicated otherwise. Baseline
values of all parameters were tested for uniformity via discriminant analysis. All data processing
and statistical analyses were performed before de-blinding the randomization order. Linear mixed
model (LMM) analysis using R statistical software package was used to determine the association
between CEUS-based microvascularity values and VISA-A scores at the 3 different time points.
For statistically significant interactions, we determined Rc2, which represents the variance explained
by the combination of fixed effects and random effects. Mixed analysis of variance (ANOVA) was
used for all other comparisons. LMM analysis was also performed to test for changes in our main
outcome variables between examination at baseline and following the 3- and 6-month intervention
periods between and within groups in a cross-over design. The LMM analysis satisfies all conditions
of an intention-to-treat analysis and has also been shown to be the most powerful statistical method
under a variety of conditions that are common to randomized controlled trials [30]. Carry-over effects
within our cross-over design were accounted for in our LMM-analyses by looking at interaction of the
order and treatment effect across time. A p value < 0.05 was considered statistically significant.
3. Results
3.1. Study Population
From September 2015 until April 2016, a total of 60 patients (32 men/28 women, age 43 ± 10 years)
with subjective Achilles tendon symptoms showed interest in our study. Following initial screening,
40 potential candidates (18 men/22 women, age 43 ± 11 years) were excluded or withdrew for the
reasons mentioned in Figure 1. A total of 20 patients (13 men/7 women, age: 44 ± 8 years, body mass
index (BMI): 24.4 ± 3.3 kg·m−2) with clinical symptoms (mean duration 54 ± 90 months) of uni- (n = 7)
or bilateral (n = 13) mid-portion Achilles tendinopathy were formally included in the study following
a detailed medical history and physical examination by a sport and exercise physician (Figure 1).
Demographic characteristics and blood test results of participants at baseline are presented in Table 1.
To evaluate homogeneity of the data at baseline between the 2 groups a discriminant analysis was
carried out. The data revealed no statistically significant differences between both study groups.
All participants wished to return to pain-free running and had either uni- or bilateral Achilles tendon
tenderness on palpation. The clinical diagnosis was based on the presence of tenderness and/or
tendon thickening 2 to 6 cm proximal to the distal insertion. One asymptomatic tendon that previously
had undergone surgery for a complete Achilles tendon rupture was excluded from our analysis.
Nutrients 2019, 11, 76 6 of 16
Table 1. Baseline-characteristics study population (n = 20).
Group AB Group BA Total
Total 10 10 20
Male/Female 5/5 8/2 13/7
Age (years) * 45.3 ± 6.4 42.0 ± 9.4 43.7 ± 8.0
Body mass index (BMI) (kg.m−2) * 23.4 ± 3.23 25.5 ± 3.3 24.4 ± 3.3
Total Cholesterol (mmol·L−1) 5.6 ± 0.7 5.2 ± 0.8 5.4 ± 0.8
Triglycerides (mmol·L−1) 1.9 ± 2.1 1.7 ± 1.1 1.8 ± 1.7
Urate (mmol·L−1) 0.3 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
Symptom duration (months) &,# 24 (0–360) 32 (0–180) 18 (0–360)
VISA-A symptomatic tendons * 58.5 ± 19.9 (n = 17) 55.9 ± 21.9 (n = 15) 57.6 ± 20.3 (n = 32)
VISA-A asymptomatic tendons * 77.0 ± 18.4 (n = 3) 88.5 ± 10.3 (n = 4) 84.7 ± 12.9 (n = 7)
VISA-A: Victorian Institute of Sports Assessment–Achilles, * mean ± SD, & median, minimum-maximum, & based
on pooled data of both symptomatic and asymptomatic tendons, # all tendons.
3.2. Change in VISA-A Scores
Changes in Achilles tendon pain and function scores during the treatment were evaluated through
the VISA-A questionnaire [26]. Baseline VISA-A scores from right and left limb were not significantly
correlated (Pearson’s R: 0.39 (95% confidence interval (CI): −0.08; 0.72), p = 0.097). VISA-A score for
the group AB at T1 was on average 60.8 (95%CI: (52.0–69.6)), similar to the group BA at T1 (62.8, 95%CI:
(54.0–71.6)). Linear mixed modeling statistics showed that after 3 months, estimated mean difference in
VISA-A score for group AB was 12.6 (95%CI: (9.7–15.5)) points, while in group BA this was 5.3 (95%CI
(2.3; 8.3)) points (Figure 2). After crossing over the AB and BA group showed an estimated mean
difference in VISA-A score of respectively 5.9 (95%CI (2.8–9.0) and 17.7 (95%CI (14.6–20.7) between
T2 and T3. Both group AB and BA achieved the same estimated mean improvement in VISA-A score
between T1 and T3 of respectively 18.5 (95%CI: (15.5–21.6)) and 23.0 (95%CI: (19.9–26.1)) (Figure 2).
Importantly, our LMM analyses showed that there was a statistically significant interaction from our
sCP randomization order ((LMM, F (2,762) = 20.3, p < 0.0001)) on change in VISA-A scores indicating a
significant difference between the groups in evolution of the VISA-A scores over time in relation to
sCP versus placebo supplementation.
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3.3. Patient Satisfaction and Return-to-Running Sports
After 3 months respectively 6 out of 10 participants in group AB and 7 out of 10 participants in
group BA reported their treatment as ‘good or excellent’. After 6 months 7 out of 9 participants in
group AB and 7 out of 9 in group BA reported being satisfied with their treatment. The success of the
intervention is also reflected in Figure 3, summarizing the number of participants that were able to
return to their desired (running) sport, although none of them was able to return to their pre-injury
level within the duration of the study. None of the participants in group AB reported that they stopped
running sport activities after switching over from sCPs to placebo.
Nutrients 2018, 10, x FOR PEER REVIEW  7 of 16 
   7 out of 9 in group BA reported being satisfied wi  their treatment. The success of 
the int rvention i  also reflected in Figure 3, summarizing the number of participan s that were able 
to return to their d sired (ru ning) spor , although n ne of them was able to return to th ir pre-
injury level within the duration of the study. None of the participants in group AB reported that 
they stopped running port activities after switching over from sCPs to placebo. 
 
Figure 3. Number of participants able to return to their running sport at T2 and T3. Due to low 
numbers Chi-square statistics were not possible on these data. 
3.4. Change in Achilles Tendon Microvascularity and Blood Markers 
Both group AB and BA showed a significant (LMM, F (2,202) = 12.8, p < 0.001) decrease in 
tendon microvascularity over the course of the intervention as assessed by CEUS. As is illustrated 
in Figure 4, there is no difference in effect between the 2 interventions and no evidence for a benefit 
of sCP supplementation on tendon vascularisation. The difference at T2 for the 2 different 
randomisation groups is only marginally significant (LMM, F (2,202) = 2.81, p = 0.062), due to the 
greater variability in group AB compared to the BA group, in particular on that time point. Our 
LMM analyses indicate a significant interaction between microvascularity and VISA-A symptom 
score over the course of the study (Rc2: 0.68; LMM, F (2,196) = 3.32, p = 0.038). Non-fasting serum 
levels of mean total cholesterol, triglycerides and uric acid were unchanged at T2 and T3 (Table 2, 
ANOVA, p > 0.05) 
 
Figure 4. Changes in microvascularity of the Achilles tendon mid-portion (2–4.5 cm from insertion) 
over time (both symptomatic and asymptomatic tendons combined). 
ber f rtici ants a le t r t r i e t l
3.4. Change in Achilles Tendon Microvascularity and Blood Markers
Both group AB and BA showed a significant (LMM, F (2,202) = 12.8, p < 0.001) decrease in
tendon microvascularity over the course of the intervention as assessed by CEUS. As is illustrated in
Figure 4, there is no difference in effect between the 2 interventions and no evidence for a benefit of
sCP supplementation on tendon vascularisation. The difference at T2 for the 2 different randomisation
groups is only marginally significant (LMM, F (2,202) = 2.81, p = 0.062), due to the greater variability in
group AB compared to the BA group, in particular on that time point. Our LMM analyses indicate a
significant interaction between microvascularity and VISA-A symptom score over the course of the
study (Rc2: 0.68; LMM, F (2,196) = 3.32, p = 0.038). Non-fasting serum levels of mean total cholesterol,
triglycerides and uric acid were unchanged at T2 and T3 (Table 2, ANOVA, p > 0.05)
Table 2. Serum blood makers at baseline (T1), 3 (T2) and 6 (T3) months.
Total Chol. (mmol·L−1) T1 (n = 20) T2 (n = 20) T3 (n = 18)
group AB 5.6 ± 0.7 5.6 ± 0.9 5.7 ± 1.1
group BA 5.2 ± 0.8 5.2 ± 1.1 5.4 ± 0.6
Triglycerides (mmol·L−1) T1 (n = 20) T2 (n = 20) T3 (n = 18)
group AB 1.9 ± 2.1 1.6 ± 0.7 1.7 ± 0.6
group BA 1.7 ± 1.1 1.6 ± 0.8 1.6 ± 0.6
Urate (mmol·L−1) T1 (n = 20) T2 (n = 20) T3 (n = 18)
group AB 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
group BA 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
Nutrients 2019, 11, 76 8 of 16
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3.5. Compliance with Interventions and Adverse Events
In group AB, no compliance data on the daily calf strengthening exercise were available for 1
participant at both T1-T2 and T2-T3. In group BA, compliance data on the daily calf strengthening
exercise were missing for 1 participant (T1-T2), 1 participant (T2-T3), and 1 participant (T1-T2 and
T2-T3). Based on the available exercise diaries, both groups AB and BA showed and achieved a similar
compliance of respectively 84 ± 11% and 78 ± 14% (p = 0.326) to the twice-daily calf-strengthening
exercises over the 6 months intervention period.
In group AB, no compliance data regarding intake of investigational product were available for
1 participant at both T1-T2 and T2-T3. In group BA, compliance data were missing for 3 participants
(T1-T2) and 1 participant (T2-T3). Compliance to intake of sCPs and/or placebo was respectively 89
± 15% and 91 ± 9% (p = 0.906) for group AB and BA over the 6-month intervention period. At T2,
6 out of 10 in group AB and 4 out of 10 in group BA correctly guessed their allocation to active or
placebo supplement. At T3, 4 out of 9 in group AB and 5 out of 9 in group BA correctly guessed
their allocation to active or placebo supplement. A total of 1 participant in group BA reported minor
gastro-intestinal discomfort after ingestion of the investigational product during the first week of the
treatment whilst using the placebo. Following a medical check-up with an independent physician
who was deblinded for the randomization order of this participant, it was decided that there was no
clear association with the dietary intervention and this participant was advised to continue with the
trial. After 1 week, a medical follow-up learned that all gastro-intestinal symptoms had disappeared.
Except for mild delayed onset muscle soreness of the calf muscles in response to the eccentric exercise,
no other adverse events were reported during the course of the intervention.
4. Discussion
The main finding of this small-scale but well-controlled pilot study is that oral supplementation
of sCPs with high glycine content may accelerate the clinical benefits of a well-structured
calf-strengthening and return-to-running program in patients with uni- or bilateral chronic Achilles
tendinopathy symptoms. Although the study was not powered to detect differences in VISA-A scores
or return-to-running sport activities between the 2 groups, it is interesting to note that, independent
of randomization order, both clinical outcome variables appear to improve more during the sCPs
supplementation period. Although the differences between the 2 groups at 3 months may appear
small, the mean change in VISA-A score in group AB of 12.6 (9.7; 15.5) points is well above the
minimum clinically important difference (MCID) of 6.5 for Achilles tendinopathy patients [31]. In our
placebo group BA, VISA-A increased only by 5.3 (2.3; 8.3) points after 3 months, which is below the
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MCID of 6.5. After crossing over from sCP to placebo and vice versa, group AB and BA showed
an opposite response with, subsequently, a significant increase in VISA-A of respectively 5.9 (2.8;
9.0) and 17.7 (14.6; 20.7). These clinical findings extend on two earlier studies [32,33], that reported
respectively a pain modulating and in vitro anti-inflammatory effect of a nutraceutical containing
collagen, mucopolysaccharides and vitamin C. Furthermore, in a rodent model of collagenase-induced
Achilles tendinopathy, a 5% glycine-rich diet for 3 weeks improved hydroxyproline, glyosaminoglycans
and non-collagenous protein content of the Achilles tendon [12]. Glycine has also been shown to
improve collagen matrix organisation strength and tenocyte remodelling, most likely by modulating
both TNF-alpha, matrix metalloproteases and the availability of collagen precursors [14]. As the sCP
supplement in the present study contains 22% of glycine [11], it could be postulated that the increased
intake of 1.1 g of glycine per day may have contributed to observed clinical improvements in VISA-A
scores during sCP supplementation. Due to nature of the co-intervention, a true washout period to
bring participants back to their baseline condition is in Achilles tendinopathy patients not possible.
From a pharmacokinetic perspective, the serum hydroxyproline content following the ingestion
of hydrolysed collagen peptides returns to baseline within 12 h [25]. Nevertheless, any potential
carry-over effects have been accounted for in our LMM-analyses by looking at interaction of the order
and treatment effect across time.
Given the small scale of the study and unequal distribution of men and women in our 2 study
groups, there is a potential of selection bias. Although the adaptability of tendon to loading differs in
men and women [34], we are not aware of any intervention study that specifically showed clinically
relevant gender difference in VISA-A scores following a calf-strengthening program. To evaluate
homogeneity of the data at baseline between the 2 groups a discriminant analysis was carried out.
The data revealed no statistically significant differences between both study groups. Unfortunately,
the relatively low number of female participants does not allow for a gender-based inference.
As women may be more prone to develop Achilles tendinopathy [35,36], future random-controlled
trials (RCTs) should aim to include an equal number of men and women in both study arms.
In order to maximize any potential synergistic effect of orally ingested sCPs with bi-daily
calf-strengthening exercises (as per Alfredson’s protocol) on tendon collagen synthesis, our participants
were instructed to ingest the sCPs 30 min before each exercise session. About 15–30 min after oral
ingestion of collagen hydrolysates, free and peptide forms of serum hydroxyproline levels significantly
increase and reach a maximum after 30–60 min and are almost back to baseline level after 7–12 h [25,37].
Although this was not investigated as a separate outcome measure, the small time window between the
bi-daily intake of a sachet with 2.5 g of sCPs and the calf-strengthening exercise may have contributed
to the high compliance rate observed in our trial. A recent proof-of-concept study by Shaw et al. (2017)
showed a dose-dependent improvement of collagen metabolism in ligaments by the oral administration
of gelatine 60 min before jumping exercises [7]. This specific time window was based on the fact that
peak availability of free and peptide forms of serum hydroxyproline is respectively 1 and 2 h following
the oral ingestion of gelatin [38]. Based on the new insight that the stimulation of exercise-induced
anabolic processes might be influenced positively by the oral administration of sCPs immediately
before an exercise program [7], we recommend that future study designs should take absorption
kinetics of the available forms of gelatin or sCPs into consideration.
A strength of the present study is that there were only 2 dropouts after T2, 1 in each group, which
is a negligible number. Given that our LMM approach operates on a missing at-random-assumption,
we deemed the reasons for dropout not violating the assumptions of the model. Furthermore,
attrition is low and no individuals were excluded from our LMM so the possibility of selection bias
is considered low in the present study. Nevertheless, as the clinical improvements in VISA-A scores
after 3 months are in the same range as previously published studies on eccentric calf-strengthening
programs [39], no firm conclusions can be drawn regarding the added benefits of sCP supplementation
in chronic Achilles tendinopathy. So, although the present randomized controlled and double-blinded
crossover study found a significant interaction of sCP supplementation on change in VISA-A score
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during a 6-month calf-strengthening plus structured return-to-running program, our findings require
duplication in a larger and adequately powered clinical trial.
From a clinical perspective, it is important to note that the majority of our participants
had a relatively long history of mid-portion Achilles tendinopathy not responding to rest or
other physiotherapy regimes. The latter is also reflected by the fact that placebo group BA only
showed a clinically relevant improvement in VISA-A score after they were switched over to sCPs
supplementation. This cross-over effect indicates that sCPs supplementation could be a useful adjunct
therapy in Achilles tendinopathy patients whom are not responding to a well-standardized eccentric
calf strengthening exercise program.
To improve our understanding of the in vivo working mechanism of specific collagen peptides,
we also investigated the microvascular changes of the Achilles tendon using a novel medical imaging
technique based on contrast-enhanced ultrasonography. The present study is the first of its kind
showing that objectively quantified Achilles tendon microvascularity is inversely and moderately
associated with Achilles tendon symptoms throughout the course of a therapeutic intervention.
The latter indicates that CEUS of tendons may be a useful and more objective medical imaging
technique to monitor the clinical response to a therapeutic intervention. Although a previous
publication showed that CEUS has a better sensitivity in detecting microvascular abnormalities
as compared to power Doppler ultrasound (PDU) [18], the observed change in CEUS-based
microvascularity during the course of the intervention was not associated with the intake of specific
collagen peptides. Our rather large inter-subject variability in Achilles tendon microvascularity
at baseline may have precluded detecting any statistically significant differences between the
2 groups. Nevertheless, our results are well in line with several other PDU-based imaging studies
that reported rather equivocal responses in microvascularity following conservative treatment of
Achilles tendinopathy [40–44]. Despite the longitudinally observed association between CEUS-based
microvascularity and Achilles tendon symptoms, it is unlikely that CEUS will be useful in determining
the potential in vivo working mechanism of specific collagen peptides as an adjunct treatment to a
well-structured eccentric calf strengthening exercise program.
Eccentric tendon loading has shown to be a safe and effective method to reduce pain and to
improve tendon structure [45]. Although PDU-based studies have been equivocal [40–44], eccentric
tendon loading has been shown to reduce the number of neovessels in the tendinopathic area of the
tendon matrix. The latter is considered to be an important etiological mechanism for the beneficial
outcome of a calf strengthening program as also applied in the current study [46]. Cell-line studies
have shown that tenocytes produce the antiangiogenic factor endostatin, a proteolytic fragment of
Collagen XVIII, in response to physiological mechanical load, thus limiting neo-angiogenesis [47].
Although endostatin response to eccentric loading has not been investigated in diseased tendons,
several mechanistic studies [47–49] indicate that only the right amount of tissue loading increases
endostatin expression and, as such, may reduce microvascularity as observed in the present study.
As the collagen matrix of tendon is a highly mechanosensitive tissue, cytokine homeostasis and cell
survival underlie an intimate balance between adequate biomechanical stimuli and disturbance
through load deprivation and overload. This delicate balance between tendon blood flow and
loading pattern was recently highlighted in a study by showing that the risk of developing
Achilles tendinopathy increased if blood flow increase in the tendon after running was reduced [36].
Based on these new insights, future studies on novel therapeutic strategies for tendinopathy should
preferably assess tendon blood flow response both at rest as well as following a standardized
tendon-loading protocol.
Although from a pathophysiological perspective return-to-running status and tendon
microvascularity are likely to interact, the limited statistical power of the present pilot study does
not allow us to exclude such a significant interaction using linear mixed modelling. The decision to
return to running was a function of pain reduction during single leg hopping as well as the successful
and pain-free achievement of pre-defined milestones during the course of our rehabilitation program.
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The latter can be justified by the well-established fact that progressive (and sports-specific) tendon
loading is required for successful tendon healing and return to sport [38]. Furthermore, the milestones
described in Appendix A Table A2 entailed significantly lower Achilles tendon loading than present
during pre-injury sports participation. Although the VISA-A questionnaires are designed to quantify
both activities-of-daily-living (ADL) and running-associated Achilles tendon pain, we cannot exclude
that running with incompletely healed tendon pathology may have introduced a certain level of
bias towards the overall VISA-A score. As such, for future RCTs we would recommend assessing
both ADL-dependent and running sport-dependent Achilles tendon pain on a visual analog scale as
secondary outcome measures.
Previous in vitro work on fibroblasts indicates that biosynthesis of ligament and tendon matrix
molecules, as well as elastin content can be stimulated by exposure to sCPs [50]. A recently published
shear wave elastography study indicates that, compared to controls, participants with Achilles
tendinopathy display lower Achilles tendon elastic modulus [51]. Accordingly, we recommend
that future randomized clinical trials in Achilles tendinopathy patients should include shear wave
elastography to monitor changes in tendon elasticity following the intake of sCPs.
5. Conclusions
Although this pilot study has limited statistical power and requires duplication in a larger
clinical trial, oral supplementation of sCPs may accelerate the clinical benefits of a well-structured
calf-strengthening and return-to-running program in patients with chronic Achilles tendinopathy
symptoms. Further imaging studies are required to understand the potential in vivo therapeutic
working mechanism of sCPs within tendons.
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Appendix A
Table A1. Inclusion and exclusion criteria.
Inclusion criteria
Clinical diagnosis of >2 months of uni- or bilateral chronic mid-portion Achilles tendinopathy, including pain on palpation 2–6 cm above the
insertion of the Achilles tendon upon physical examination
Active participation in sports activities
Desire to return to original level of sports
Age 18–55 years
Exclusion criteria
Clinical suspicion of insertional Achilles tendon disorders or (partial) rupture *
Clinical suspicion of plantar flexor tenosynovitis
Clinical suspicion of n.suralis pathology
Clinical suspicion of peroneal subluxation
Clinical suspicion of spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.
Condition that prevents the patients from executing an active exercise programme
Previous eccentric calf strengthening exercises
Any type of Achilles tendon injection therapy in the previous 3 months
Pregnancy
Contraindications for use of DEFINITY®contrast agent
Quinolones or statin-related tendinopathy
* partial Achilles tendon rupture was defined as a sports-related sudden-onset pain of the Achilles tendon
mid-portion with a clear discontinuity of the tendon fibres of the Achilles tendon on grey-scale ultrasound in
both the longitudinal and axial plane.
Table A2. Exercise and return-to-running program.
Eccentric calf exercise program
Exercise 1: Gastrocnemius Heel Drop
Hold onto something stable for balance.
Begin with the heel raised and knee straight
Slowly lower the heel below the step
Push up to the starting position by using the uninjured leg
Perform 3 × 15 repetitions, 2 × daily, 7 days/week.
Exercise 2: Soleus Heel Drop
Hold onto something stable for balance.
Begin with heel raised and knee bent
Slowly lower the heel below the step
Push up to the starting position by using the uninjured leg
Perform 3 × 15 repetitions, 2 × daily, 7 days/week
What Should I Expect to Feel After the Exercise?
When performed properly, this exercise program is going to cause some tendon and muscle soreness, especially during the first one to two
weeks. Studies have shown that it is a safe training program with no risk of new injuries. The soreness will become much less as you
progress with the exercises over the course of weeks.
Please STOP the program and contact your physician or physiotherapist if you experience significant pain or discomfort.
When you can perform the exercise without experiencing any pain or discomfort, start to increase the weight. This can be achieved by
using a calf raise machine, wearing a weighted back pack or vest.
Add 5 kg per week until at 60 kg.
Physiotherapy Follow-up Protocol for Return to Running
4 week review
All been given Alfredson program
Hop pain less than 1–2/10 can commence running
2 times/week
Shuffle-Jog warm up 5 mins on grass
3 sets of 5 run throughs 80 m (or equivalent) 50–60% pace on grass
Rolling start
No more than 20% increase in distance per week
3 sets 6 reps
4 sets 5 reps
Should be no pain by 3rd run through
Repeat over 3 weeks
If pain is increased overall, rest a week, return to exercises and then recommence as above
If Ok progress to 3 sessions/week (every second day)
Shuffle-Jog warm up 5 mins on grass
4 sets 6 run throughs 80 m ( or equivalent) 55–65% pace on grass
4 sets 7 reps or equivalent distance (one session may be steady state)
4 sets 8 reps or equivalent distance (one session may be steady state)
Repeat 3 weeks
Review at 6 weeks
Tailored approach to return to pre- baseline/ aspirational training loads
Educational support regarding realistic goals
Weekly increase limited to 7–10% increase
Review at 12 weeks
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Date of filling out questionnaire:
( ) - 3 months after starting treatment
( ) - 6 month after starting treatment
Dear participant,
Through the following brief questionnaire we would like to assess your opinion on the treatment that you
have been given over the past 3 months.





The groups "excellent" and "good" were regarded as successful and the groups of "moderate" and "poor" as not
successful.
Could you please indicate underneath whether you have been able to return to sports in the past 3 months?
A. I am or have not been active in sports
B. I have not been able to return to sports
C. I have been able to return to sports but not in my desired sport
D. I have been able to return to my desired sport, but not yet at my old level
E. I have been able to return to my old level in the desired sport.
The groups "D" and "E" were regarded as successful and the groups of "A, B or C" as not successful.
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